"CSL Seqirus was negatively impacted by significantly low influenza immunisation rates, particularly in the United States. "CSL Vifor grew sales, underpinned by robust iron volumes in Europe and the expansion of our nephrology products." Needs to lift Despite the positive outlook coming from the company, Josh Gilbert, market analyst at eToro, has said the company needs to lift in the second half. "CSL delivered a disappointing set of first-half FY25 results, missing consensus estimates on both revenue and profit. "Revenue rose 5% to $8.48 billion, while NPATA increased just 3% to $2.07 billion — both falling short of expectations, largely due to weakness in its Seqirus vaccine division. "There were some positives, but the market will likely focus on the headline miss. The standout was CSL Behring, its core revenue driver, which posted a 10% increase in sales alongside improving margins.